0001209191-23-054910.txt : 20231109 0001209191-23-054910.hdr.sgml : 20231109 20231109203509 ACCESSION NUMBER: 0001209191-23-054910 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231107 FILED AS OF DATE: 20231109 DATE AS OF CHANGE: 20231109 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McCormac Paul CENTRAL INDEX KEY: 0001994981 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41855 FILM NUMBER: 231394341 MAIL ADDRESS: STREET 1: C/O LEXEO THERAPEUTICS, INC. STREET 2: 345 PARK AVENUE SOUTH, 6TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Lexeo Therapeutics, Inc. CENTRAL INDEX KEY: 0001907108 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 854012572 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 345 PARK AVENUE SOUTH STREET 2: FLOOR 6 CITY: NEW YORK STATE: NY ZIP: 10010 BUSINESS PHONE: (212) 547-9879 MAIL ADDRESS: STREET 1: 345 PARK AVENUE SOUTH STREET 2: FLOOR 6 CITY: NEW YORK STATE: NY ZIP: 10010 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-11-07 0 0001907108 Lexeo Therapeutics, Inc. LXEO 0001994981 McCormac Paul C/O LEXEO THERAPEUTICS, INC. 345 PARK AVENUE SOUTH, FLOOR 6 NEW YORK NY 10010 0 1 0 0 Chief Technical Officer 0 Common Stock 2023-11-07 4 C 0 3191 A 17349 D Series B convertible preferred stock 2023-11-07 4 C 0 29061 D Common Stock 3191 0 D Upon the closing of the Issuer's initial public offering, each share of Series B convertible preferred stock automatically converted into shares of the Issuer's common stock on a one-for-9.106601 basis, which reflects an anti-dilution adjustment to the conversion ratio pursuant to a provision of the Series B convertible preferred stock based on the pricing of the initial public offering (as described in the Reporting Person's Form 3). The shares had no expiration date. /s/ Jenny Robertson, Attorney-in-Fact 2023-11-09